Can engineered immune cells tame a debilitating autoimmune disease?

This phase 1 trial is testing an experimental therapy called SYS6020 for people with refractory generalized myasthenia gravis, a chronic autoimmune condition that causes severe muscle weakness. SYS6020 uses a patient's own immune cells, engineered to target BCMA, a protein involved in producing the antibodies that drive the disease. The study aims to see if this treatment is safe and tolerable, and whether it can improve symptoms, with participants receiving multiple infusions and being followed for up to five years.